AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer
May 30, 2023 08:00 ET
|
AUM Biosciences Pte Ltd
SINGAPORE and BETHESDA, Md., May 30, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on discovering and developing precision...
AUM Biosciences to Participate in Inaugural EF Hutton Global Conference
April 26, 2023 09:00 ET
|
AUM Biosciences Pte Ltd
SINGAPORE and BETHESDA, Md., April 26, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on advancing a pipeline of precision oncology...
AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma
January 05, 2023 08:00 ET
|
AUM Biosciences Pte Ltd
SINGAPORE and BETHESDA, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology...
AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma
November 30, 2022 08:00 ET
|
AUM Biosciences Pte Ltd
SINGAPORE and BETHESDA, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology...
AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia
November 15, 2022 08:00 ET
|
AUM Biosciences Pte Ltd
SINGAPORE and BETHESDA, Md., Nov. 15, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline...
AUM Biosciences to Participate in BioCentury-BayHelix East-West BioPharma Summit
November 04, 2022 08:30 ET
|
AUM Biosciences Pte Ltd
SINGAPORE and BETHESDA, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical-stage pipeline of precision oncology...
AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V
October 20, 2022 05:00 ET
|
AUM Biosciences Pte Ltd
The transaction reflects a pre-money equity value of $400 million for AUM BiosciencesTransaction is expected to provide $69 million of gross proceeds (assuming no redemptions by Mountain Crest...
AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene
August 18, 2022 08:00 ET
|
AUM Biosciences Pte Ltd
SINGAPORE and BETHESDA, Md., Aug. 18, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing precision oncology therapeutics,...
AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer
June 07, 2022 08:00 ET
|
AUM Biosciences Pte Ltd
SINGAPORE and BETHESDA, Md., June 07, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing precision oncology therapeutics, today...
AUM Biosciences Appoints an industry veteran, Scott Jordan as Head of Corporate Development
May 17, 2022 08:00 ET
|
AUM Biosciences Pte Ltd
BETHESDA, Md., May 17, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company focused on advancing a clinical pipeline of precision oncology therapeutics designed to...